As Parkinson’s disease advances, patients frequently experience variations in motor abilities throughout the day. For those facing reduced efficacy towards the end of the dosing interval (dose gaps) the OraFID^® dispenser provides an enhanced opportunity to fine tune levodopa treatment.

This combination of drug and device allows for dosing adjustments to address each patient’s specific requirements at any given time, thereby minimizing the risk of under- or overdosing and associated side effects. It offers a simplified approach to achieving precise medication delivery.

Kathrine Gamborg Andreassen, CEO of Navamedic ASA, states: “This concept reflects our unwavering commitment to be a proud contributor to public health by improving patient outcomes through personalized treatment solutions, utilizing minitablets.”

Navamedic ASA will oversee the launch and marketing in Sweden, Norway and Denmark. Orion Corporation (“Orion”) has been granted exclusive rights to market, distribute, and sell the product across 27 European countries. As the marketing authorization (MA) holder within their designated territory, Orion will assume all associated rights and responsibilities.